Senesco Technologies, Inc.

Dominic O Cliche

John E Thompson

Catherine Taylor

Tzann-Wei Wang

John C Carlson

Richard Narayansingh

Larry Petrov

Bruce C Galton

Adrienne Boone

Elizabeth Heikkila

John Gerard Flanagan

Shelley Culp-Stewart

Marianne Kaup

Michelle Senchyna

Charles A Dinarello

Leonid Reznikov

Marianne Hopkins

Benjamin Pomerantz

Diana Michelle Senchyna

Elisabeth M Heikkila

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.

siRNA useful to supress expression of EIF-5A1

The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.

Method for inducing apoptosis using apoptosis-specific EIF5-A

Expression vector encoding apoptosis-specific eIF-5A

Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1

The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.

Nucleic acids, polypeptides, and methods for modulating apoptosis

Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Growing community of inventors

Marieville, Canada

Dominic O Cliche